Myostatin Inhibitor Peptide
GDF-8 Propeptide Fragment
Overview
Myostatin inhibitor peptides are synthetic fragments derived from the myostatin propeptide — the natural endogenous inhibitor that is cleaved from myostatin during processing and remains bound to it limiting its activity. By mimicking the propeptide these fragments competitively inhibit myostatin binding to its receptor without the broad activin-inhibiting effects of follistatin. Research peptide formulations targeting myostatin inhibition represent one of the most actively pursued areas in muscle-building peptide science with multiple pharmaceutical programs targeting this pathway for muscular dystrophy sarcopenia and cachexia.
Mechanism of Action
Myostatin (GDF-8) is synthesized as an inactive precursor that is proteolytically cleaved to release the mature active dimer. The propeptide remains non-covalently associated with the mature domain keeping it in a latent complex. Myostatin inhibitor peptides derived from this propeptide sequence compete for binding to the mature myostatin dimer preventing it from engaging its receptors ActRIIA and ActRIIB on muscle cells. This receptor blockade prevents SMAD2/3 phosphorylation and the downstream suppression of protein synthesis and satellite cell activation that myostatin normally induces. Unlike follistatin which inhibits multiple TGF-beta family members myostatin-specific peptides are more targeted potentially offering muscle growth benefits with a better selectivity profile. Pharmaceutical anti-myostatin antibodies (like domagrozumab and landogrozumab) validate this target though results in clinical trials for muscular dystrophy have been more modest than animal models suggested.
Where does Myostatin Inhibitor Peptide sit?
See how this peptide compares across all 85 peptides in our database.
Dosage Information
Typical Dose
Research compound — no established dosing
Frequency
N/A
Administration
Subcutaneous injection in research settings
Notes
Multiple pharmaceutical-grade anti-myostatin biologics in clinical trials. Research peptide market has various formulations with limited characterization. Clinical trial results for muscular dystrophy indications have been disappointing suggesting the pathway is more complex in humans than animal models.
Potential Side Effects
Community Experiences
No experiences shared yet. Be the first!
Quick Facts
- Administration
- Subcutaneous injection in research settings
- Typical Dose
- Research compound — no established dosing
- Frequency
- N/A
- References
- 0 curated + 8 from PubMed
- Evidence Score
- 13.6 / 100